Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.72 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.53 |
| ▸ | TUBB | P07437 | 1/20 | 0.53 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.53 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.53 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.53 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.53 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.53 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.53 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.53 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.53 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.53 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.53 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.53 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.53 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8770557 | 0.95 | MAOB (0.66) | MAOBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL8769745 | 0.91 | MAOB (0.72) | MAOBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL8775403 | 0.89 | MAOB (0.69) | MAOBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL21254583 | 0.87 | MAOB (0.66) | MAOBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL18808351 | 0.85 | MAOB (0.71) | MAOBMEN1KMT2ACHRNA7SMN1; SMN2 | |
| SCHEMBL15887043 | 0.84 | MAOB (1.00) | MAOBMEN1KMT2ACHRNA7RAB9A | |
| SCHEMBL27887307 | 0.83 | TUBB4A (0.70) | MAOBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL17322470 | 0.81 | MAOB (0.80) | MAOBMEN1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL8569571 | 0.80 | MAOB (0.60) | MAOBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL16131037 | 0.80 | MAOB (0.60) | MAOBTUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9622991-B2 | Hematopoietic growth factor mimetic small molecule compounds and their uses | LIGAND PHARMACEUTICALS INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9622991-B2 | Hematopoietic growth factor mimetic small molecule compounds and their uses | LIGAND PHARMACEUTICALS INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9144557-B2 | Hematopoietic growth factor mimetic small molecule compounds and their uses | LIGAND PHARMACEUTICALS INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9144557-B2 | Hematopoietic growth factor mimetic small molecule compounds and their uses | LIGAND PHARMACEUTICALS INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20150252043-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-09-10 | — | — | US | disclosed |
| US-20150252043-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-09-10 | — | — | US | disclosed |
| US-20140243324-A1 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243324-A1 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-08-28 | — | — | US | disclosed |
| EP-2642994-A2 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | Ligand Pharmaceuticals Incorporated (US) | 2013-10-02 | — | — | EP | disclosed |
| US-20120295904-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | LIGAND PHARMACEUTICALS INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295904-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | LIGAND PHARMACEUTICALS INC. (US) | 2012-11-22 | — | — | US | disclosed |
| EP-2488486-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | Ligand Pharmaceuticals Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| WO-2012068406-A2 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012068406-A2 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2011046954-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | LIGAND PHARMACEUTICALS INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011046954-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | LIGAND PHARMACEUTICALS INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243324-A1 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | HGF, EPOR, MPL | MAOB 4300/4885TUBB4A 1381/4885TUBB 1201/4885 |
| US-20150252043-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | MPL, CSF3R, HGF | MAOB 4439/4885TUBB4A 2510/4885TUBB 2473/4885 |
| US-20120295904-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | MPL, CSF3R, HGF | MAOB 4439/4885TUBB4A 2510/4885TUBB 2473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.